Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Rare Melanoma Shows Sensitivity to Immune Therapy
Disease Discoveries

Rare Melanoma Shows Sensitivity to Immune Therapy

By Will DossFeb 7, 2018
Share
Facebook Twitter Email
Jeffrey Sosman, MD, professor of Medicine in the Division of Hematology and Oncology, was a co-author on a new study that sheds light on the molecular foundations of a rare type of skin cancer, acral lentiginous melanoma.
Jeffrey Sosman, MD, professor of Medicine in the Division of Hematology and Oncology, was a co-author on a new study published in the journal Nature.

Specialized antibodies appear to be highly effective in treating desmoplastic melanoma, a rare type of melanoma, according to a study published in the journal Nature.

The antibodies, called anti-programmed destruction 1 (anti-PD1) and anti-programmed destruction ligand 1 (anti-PD-L1), release the immune system to attack cancer cells by blocking immune checkpoints on immune cells. Patients with desmoplastic melanoma (DM) who were treated with this immune checkpoint blockade (ICB) therapy had a better-than-expected benefit in response to the treatment.

The study was co-authored by Jeffrey Sosman, MD, professor of Medicine in the Division of Hematology and Oncology. Sosman is also head of the Melanoma Program and co-leader of the Transitional Research in Solid Tumors Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

DMs account for fewer than four percent of all melanomas and are characterized by resistance to chemotherapy and a high number of mutations in their genes, the mutations being a product of long-term sun exposure. In addition, DM’s dense and scarred tissue has been thought to limit the usefulness of immune therapies, making it a difficult cancer to effectively treat.

Previous studies have found that ICB therapy produces better results in a number of cancers with a high burden of mutations — including melanoma, lung cancer and bladder cancer — making it a prime candidate for treating DM.

The investigators examined pathology reports from over 1,000 melanoma patients, finding 60 who had advanced DM and were treated with ICB therapy. While only 35 to 45 percent of melanoma patients typically respond to ICB, over 70 percent of the study group had tumors that responded to ICB, an increase in the number of patients with a clinical benefit.

Further analysis showed why the treatment worked so well: ICB treats cancer by blocking a surface protein on immune cells called PD-1, preventing its interaction with another protein, PD-L1, on cancer cells. The interaction of PD-1 with PD-L1 turns off the immune cell. This is prevented with these anti-PD-1 antibodies.

By blockading PD-1 and preventing its binding to PD-L1, ICB was able to greatly improve the clinical outlook in patients with DM. In fact, it was among the highest rate of responses to any PD-1 blockade therapy in any type of cancer, according to the study.

Further investigation into the relationship between a cancer’s ability to fool the body’s immune system and the success of ICB may improve personalized cancer care, according to Sosman.

“The next step is to prove these patients with DM are able to benefit in a prospective study,” Sosman said. “This study is now actively enrolling patients with either locally advanced or metastatic desmoplastic melanoma in the skin cancer program at Northwestern and offers a potential benefit for those patients.”

This study was funded in part by the Grimaldi Family Fund, the Parker Institute for Cancer Immunotherapy, National Institutes of Health (NIH) grants R35 CA197633 and P01 CA168585, the Ressler Family Fund, the Samuels Family Fund and the Garcia-Corsini Family Fund.

Patients or physicians interested in the desmoplastic melanoma trial can contact cancertrials@northwestern.edu or call 312-695-1102, or view a list of active clinical trials at the Lurie Cancer Center.

Cancer Dermatology Immunology Research
Share. Facebook Twitter Email

Related Posts

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

Comments are closed.

Latest News

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.